$SOTK

Sono-Tek Corp (SOTK) VP awarded 12,968 stock options

Sono-Tek Corp (SOTK) reported that VP Christopher Cichetti received 12,968 stock options with an exercise price of $5.35, exercisable from 2027-08-20 and expiring on 2036-08-20. He now holds 92,731 options in total.

Original reporting
Published Aug 24, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SOTK
Neutral
high confidence
Mentioned
$SOTK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SOTKNeutralLow
01

Why it matters

The grant is a routine compensation event; no material change to company fundamentals.

02

Market read

Low relevance; the disclosed transaction is small and unlikely to affect market perception.

03

What to watch

Potential future dilution if many options are exercised, but impact remains limited.

Relevance 4/10Novelty 3/10Timing: post‑transaction 2026‑08‑20

Background

Form 4 filing discloses an insider option grant to Sono‑Tek Corp's vice president.

Company-level read

Ticker impact

$SOTKNeutralHigh confidence
Context

Vice President Christopher Cichetti was granted 12,968 Sono‑Tek options at $5.35 per share, increasing his holdings to 92,731 options.

Expected impact

Minimal impact; unlikely to move the stock price.

Evidence & confidence

The grant size ($69K) is trivial relative to market cap and does not signal material change in ownership or strategy.

Market effects

None

None

None

Counterpoint

The grant could be viewed as a routine compensation event with no trading edge.

Key entities

  • Christopher Cichetti

    Vice President of Sono‑Tek Corp receiving the option grant.

  • Sono‑Tek Corp

    Issuer of the options.

Related articles

$SOTKMed

Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems First Half Revenue Increased 6% to $10.9 Million; Gross Margin Expanded to 55%; Operating Income Increased 41%; Medical Market Sales

$SOTKMed

Sono-Tek stock rises on record $3.6M production line order

Sono-Tek Corp (NASDAQ:SOTK) shares rose 3.9% premarket after the company said it received a $3.6 million order for an integrated advanced manufacturing production line for medical diagnostic device coating. Sono-Tek said it is its largest single-line order, placed by an existing customer moving to high-volume manufacturing, with shipment expected in fiscal 2028.

$SOTKMedAI 8/10

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek (Nasdaq: SOTK) reported first-quarter fiscal 2027 results for the quarter ended May 31, 2026. Net sales rose 10% to $5.66 million, gross margin expanded to 57% from 52%, operating income increased 86% to $897,000, and net income rose to $741,000 ($0.05 diluted). Cash was $16.65 million with no debt, and backlog was $7.73 million. The company expects continued 1H growth driven by medical demand and higher-value production systems.

$SOTKMed

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm SONO-TEK CORPORATION REPORTS FIRST QUARTER FISCAL 2027 RESULTS Exhibit 99.1 Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67% Anticipati

$SOTKMedAI 9/10

Sono-Tek Corporation Q4 2026 Earnings Call Summary

Sono-Tek Corporation reported Q4 2026 results driven by a shift to higher-ASP, turnkey production systems. The company said medical demand rose 54% year over year, while clean energy orders fell 19% amid government policy changes. Gross margin increased to 51% and operating income rose 81%. Management projected growth and profitability in fiscal 2027 H1, with flat-to-modestly higher full-year revenue amid clean-energy uncertainty. Cash was $14.8 million with no debt.